MASLD/MASH Learning Center
Podcast: Best Practices For MASH Patient Identification
April 2026
Stay up to date on MASH and MASLD with expert insights from nurse practitioners Sarah Dawkins of Duke University Medical Center and Edith Johannes of UCLA Health. This episode focuses on best practices for identifying at-risk patients, including those with steatosis on imaging, cardiometabolic risk factors, and elevated BMI—highlighting why early screening is critical to preventing progression to cirrhosis and liver transplant. Learn how to apply practical, non-invasive tools like FIB-4 and FibroScan to assess fibrosis risk, when to refer patients, and how to navigate common challenges such as intermediate scores and normal liver labs. With MASH becoming a leading cause of liver disease, this discussion provides actionable strategies for advanced practice providers and primary care clinicians to improve early detection and patient outcomes. Visit the GHAPP Digital Hub and GHAPP ACE app for more educational content.
Watch Now
Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?
April 2026
Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specialists Robin Soto and Alison Moe break down how to set realistic expectations, define meaningful treatment goals beyond the scale, and guide patients through long-term lifestyle and pharmacologic management. Discover why success in MASH care extends beyond weight loss to include improvements in A1C, lipid profiles, energy levels, sleep, and overall metabolic health, and how shifting the conversation away from numbers can improve patient motivation and adherence. This episode also explores how to structure patient journeys through the first 30, 60, and 90 days of treatment, navigate common challenges with compliance, and reinforce sustainable behavior change. Gain insights into emerging therapies, including newly approved medications targeting liver fat and fibrosis, as well as GLP-1 receptor agonists that support both metabolic health and liver outcomes. The discussion highlights how to personalize treatment plans, manage side effects, and empower patients to take control of their disease while preventing progression to cirrhosis and liver-related complications.
Watch Now
Lessons Learned in 2025 MASLD Care
February 2026
In this video, Michelle Barnett, PA-C, a hepatology physician assistant in Colorado Springs, reflects on key lessons learned in the evolving management of MASLD and MASH as we enter 2026. She clarifies updated terminology distinguishing MASLD and MASH from MetALD, helping primary care clinicians better identify patients with metabolic risk factors with and without regular alcohol use. The discussion highlights the impact of the November 2025 updates from American Association for the Study of Liver Diseases, which aim to improve disease awareness, risk stratification, and earlier referral. Michelle also shares real-world clinical experience with liver-directed therapy, including outcomes observed after more than a year of treatment with resmetirom, and reviews the FDA approval of semaglutide for patients with F2–F3 fibrosis, setting the stage for future combination therapy. The video reinforces lifestyle modification as the foundation of long-term MASLD management, outlining evidence-based recommendations for weight loss, exercise, and dietary interventions such as the Mediterranean diet. This practical update provides clinicians with actionable insights into current and emerging strategies for managing steatotic liver disease and staying current as guidelines continue to evolve.
Watch Now
Cardiovascular Disease in Patients With MASLD/MASH
February 2026
This video explores the critical relationship between cardiovascular disease and patients with MASLD and MASH, highlighting why cardiovascular risk—not liver failure—is the leading cause of mortality in this population. Oyin Penny, NP, discusses the importance of aggressive risk factor management, including lipid control, blood pressure optimization, and glucose management, and reframes these strategies as liver-protective therapies. The discussion emphasizes the need for a multidisciplinary approach to care and clarifies the safety and benefits of statin therapy in MASLD and MASH, including their role in reducing cardiovascular risk and hepatic inflammation. The video also reviews important drug–drug interactions, specifically how resmetirom can affect statin metabolism through CYP2C8 inhibition and why statin dose adjustments may be necessary. This practical overview reinforces that MASLD is not a reason to avoid statins—but a reason to prescribe them—and provides actionable insights for clinicians managing cardiometabolic risk in patients with fatty liver disease.
Watch Now
Alcohol and MASLD/MASH: Navigating the Complex Relationship
November 2025
In this insightful session from the GHAPP MASLD Community Network, Alison Moe, PA-C, dives into the complex and often misunderstood relationship between alcohol use and metabolic dysfunction–associated steatotic liver disease (MASLD). Drawing from clinical experience, Alison explains why accurately screening, quantifying, and discussing alcohol consumption with patients is essential to understanding disease progression, treatment eligibility, and overall liver health. She outlines how continued alcohol use can alter liver function tests (LFTs), confound noninvasive test results, and affect candidacy for emerging MASH pharmacotherapies. Viewers will learn how to approach sensitive conversations about drinking habits without stigma, interpret AASLD alcohol threshold guidelines, and apply effective counseling strategies for patients with combined alcohol-related and metabolic liver disease. Alison also discusses the role of PEth urine testing, lifestyle counseling, and the importance of complete abstinence for those with advanced fibrosis. This educational talk provides clinicians with actionable insights to support patients in improving their metabolic and liver health through honest communication, behavioral change, and evidence-based management.
Watch Now
NITs: A Practical Overview: Navigating the Basics
November 2025
Learn how non-invasive testing (NITs) is transforming fibrosis assessment in patients with MASLD and MASH. In this educational talk, Sarah Dawkins, NP, from Duke University Liver Clinic, breaks down the differences between simple steatosis (MASLD) and steatohepatitis (MASH), explains when and how to use serum-based tests like FIB-4 and ELF, and explores the advantages and limitations of imaging tests such as FibroScan and MRI elastography. Discover how to interpret results, avoid false positives, and determine when hepatology referral or biopsy is needed. Perfect for clinicians managing metabolic liver disease and looking to integrate non-invasive testing into everyday practice.
Watch Now
Motivational Interviewing: Practical Techniques For Lifestyle Adherence
November 2025
In this engaging session from the GHAPP MASLD Community Network, Erin Tanner, DNP, from Gastro Health in Birmingham, Alabama, discusses how motivational interviewing can empower patients with fatty liver disease to make meaningful lifestyle changes. Drawing from over 14 years of experience in hepatology and gastroenterology, Erin explains how a collaborative, patient-centered approach can improve adherence to diet, exercise, and weight management plans. Using the RULE framework—Resist the righting reflex, Understand motivation, Listen with empathy, and Empower the patient—she demonstrates practical ways to foster trust and promote behavior change without judgment. Erin also introduces the SMART goals method (Specific, Measurable, Achievable, Relevant, Time-bound), guiding clinicians on how to set realistic, personalized goals that patients can achieve and sustain. Through reflective listening, affirmation, and consistent follow-up, providers can help patients overcome ambivalence, build confidence, and stay motivated on their journey to better liver and metabolic health.
Watch Now
Diagnostic Workup: What Tests and When?
November 2025
In this educational session from the GHAPP MASLD Community Network, Erin Parkinson, APRN, from the Transplant Institute at Tampa General Medical Group, provides a detailed walkthrough of the diagnostic workup for metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). With experience in both general and transplant hepatology, Erin explains how to identify and evaluate patients at risk—beginning with key metabolic risk factors such as obesity, diabetes, and hypertension, and moving through the essential steps of imaging, laboratory testing, and fibrosis assessment. Viewers will learn when and how to use tools like ultrasound, FIB-4, FibroScan, ELF testing, and MR elastography to differentiate mild disease from advanced fibrosis or cirrhosis. Erin also emphasizes the importance of quantifying alcohol intake, ruling out viral, autoimmune, and genetic liver diseases, and applying risk stratification to determine appropriate follow-up and hepatology referral. This comprehensive overview equips APPs and clinicians with the practical framework needed to confidently diagnose, stage, and monitor MASLD and MASH, while incorporating HCC screening and long-term management strategies for high-risk patients.
Watch Now
MASH/MASLD in Type 2 Diabetes: Concurrent Medication Management
November 2025
In this in-depth educational discussion from the GHAPP MASLD Community Network, Allysa Saggese, NP, from Weill Cornell Medicine in New York City, explores the critical intersection between type 2 diabetes, metabolic dysfunction–associated steatotic liver disease (MASLD), and metabolic dysfunction–associated steatohepatitis (MASH). Allysa explains why patients with diabetes are at higher risk for developing MASH and advanced fibrosis, detailing how insulin resistance, excess glucose, and fat accumulation drive inflammation and liver damage. She reviews the most common diabetes medication classes—including metformin, GLP-1 receptor agonists, SGLT2 inhibitors, TZDs (pioglitazone), and DPP-4 inhibitors—and discusses their impact on liver fat, inflammation, and fibrosis, highlighting which options offer the most dual benefit for both glycemic and liver health. Viewers will learn how to approach medication selection and sequencing, when to use caution in cirrhosis or decompensated liver disease, and how to tailor treatment to each patient’s metabolic profile. With clear clinical reasoning and practical insights, Allysa provides a concise roadmap for optimizing diabetes management in patients with MASLD and MASH—balancing glycemic control, liver protection, and overall metabolic wellness.
Watch Now
LFTs Demystified: A Practical Guide for APPs
November 2025
In this episode of Liver Functions Demystified, Chantil Jeffreys, FNP from Gastro One in Memphis, Tennessee, shares a practical guide for interpreting liver enzyme results and identifying when to evaluate patients for MASLD (metabolic dysfunction–associated steatotic liver disease) and MASH (metabolic dysfunction–associated steatohepatitis). Drawing from 24 years of clinical experience, she explains how to recognize key patterns such as persistent ALT and AST elevations, the significance of ALT being higher than AST in early MASH, and why associated metabolic risk factors—like type 2 diabetes, obesity, hypertension, and hyperlipidemia—make even mild elevations clinically important. Chantil also reviews the role of other markers including GGT, alkaline phosphatase, bilirubin, albumin, and INR in assessing disease severity and progression. She highlights how to differentiate MASH from alcohol-associated liver disease, viral hepatitis, and drug-induced liver injury, and underscores the importance of serial monitoring to track improvement or progression. This video offers a clear, practical framework for clinicians, APPs, and primary care providers to better evaluate and manage patients with liver disease in everyday practice.
Watch Now
NITs: A Practical Overview: Navigating the Basics
November 2025
Join Renee Pozza, a hepatology nurse practitioner with more than 25 years of experience, as she breaks down the essentials of non-invasive testing and fibrosis assessment in patients with metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH). In this educational session, Renee reviews how to identify patients early, interpret key laboratory scores such as FIB-4 and ELF, and apply imaging tools like FibroScan® and MRE to evaluate liver fat and fibrosis. Learn how to distinguish simple steatosis from progressive fibrosis, recognize markers of advanced liver disease, and integrate non-invasive tests into clinical workflows across primary care, GI, endocrinology, and hepatology settings. Renee also highlights when to consider pharmacologic interventions—including resmetirom and GLP-1 therapies—and when to refer to hepatology for advanced fibrosis or cirrhosis. For more expert-led resources on MASLD, MASH, and liver health, visit the MASLD Community Network to access webinars, clinical insights, and continuing education for advanced practice providers.
Watch Now
Diet and Nutrition: Tailoring Plans For Diverse Populations
October 2025
In this presentation, Tina Gregg, NP-C, from GI Associates, shares practical, evidence-based strategies for nutrition and lifestyle management in MASLD and MASH. With nearly two decades of experience caring for patients with liver disease, Tina emphasizes that lasting improvement requires more than telling patients to “lose weight”—it calls for tailored, culturally sensitive, and sustainable dietary guidance. She explores data supporting the Mediterranean diet, DASH diet, low- and moderate-carbohydrate approaches, intermittent fasting, and plant-based eating, detailing how each can reduce liver fat, improve insulin sensitivity, and decrease inflammation. Tina also discusses how to adapt these principles for patients’ cultural preferences, socioeconomic barriers, and comorbidities such as diabetes, CKD, and hyperlipidemia. This session, part of the GHAPP MASLD & MASH Community Network, highlights how APPs can guide patients toward realistic dietary changes that enhance both liver and metabolic health.
Watch Now